real semaglutide Ozempic® (semaglutide) GLP-1 RA for Type 2 Diabetes FDA warns consumers not to

Warnings and precautions: Consider the risk of aspiration during general anaesthesia or deep sedation

In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids. Incretin hormones are released whenever food is consumed

Adhering to the washout period is essential for cardiovascular safety, avoiding risks such as compounded blood sugar decreases or excessive gastrointestinal stress

Like all GLP 1 medicines, it works best when combined with sustainable changes to nutrition, activity, sleep, and eating habits

Setting realistic expectations about potential weight regain and developing strategies to minimise this